Yesterday marked the 23rd anniversary of my hypoparathyroidism diagnosis, and the first time I’ve finally accepted that my condition is not my fault. Logically, 41-year-old Heather knows that 18-year-old Heather isn’t responsible for this disease. It was a combination of tumors on my parathyroid glands, a birth defect that…
Discussion
Daily treatment with Yorvipath (palopegteriparatide) leads to rapid and sustained improvement in kidney function among adults with hypoparathyroidism, according to newly published data from the PaTHway trial, whose earlier results were used to back the drug’s widespread approvals. Gains in kidney health for these patients were seen regardless…
Discussion
Note: This column describes the author’s own experiences with Natpara (recombinant parathyroid hormone) and Yorvipath (palopegteriparatide). Not everyone will have the same response to treatment. Consult your doctor before starting or stopping a therapy. “Red and white, blue suede shoes/ I’m Uncle Sam, how do you do?/ Give me five,…
Discussion
Treatment for at least three years with Yorvipath (palopegteriparatide), an approved daily hormone replacement therapy used to help manage blood calcium levels in adults with hypoparathyroidism, led to sustained improvements in calcium control for patients taking part in a clinical trial. New results from the Phase 3 study,…
Get regular updates to your inbox.
